Blog

Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy

Eric Singhi/X

Jan 29, 2025, 07:45

Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy

Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Phase 2 SKIPPirr: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemo

Oral dexamethasone 8mg BID (Day -2, -1 and 1 dose 1 h pre-infusion)
IRRs ~3-fold (22.5% v 67.4%)
IMO practice-changing.”

Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study – Journal of Thoracic Oncology

Authors: Alexander I. Spira, Luis Paz-Ares, Ji-Youn Han, Jin-Yuan Shih, Céline Mascaux, Upal Basu Roy, Jon Zugazagoitia, Yu Jung Kim, Chao-Hua Chiu, Sang-We Kim, Ernest Nadal, Ignacio Gil-Bazo, Sean P. Murphy, Bailey G. Anderson, Yichuan Xia, George Wang, Joshua M. Bauml, Marc Chioda, Jairo Simoes, Parthiv J. Mahadevia, Gilberto Lopes.

Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy

Alexander I. Spira Bailey G. Anderson cancer Céline Mascaux Chao-Hua Chiu Eric Singhi Ernest Nadal George Wang Gilberto Lopes Ignacio Gil-Bazo Jairo Simoes Ji-Youn Han Jin-Yuan Shih Jon Zugazagoitia Joshua M. Bauml Luis Paz-Ares Marc Chioda OncoDaily Oncology Parthiv J. Mahadevia Sang-We Kim Sean P. Murphy Upal Basu Roy Yichuan Xia Yu Jung Kim

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer